Market Cap 36.80M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 14,956
Avg Vol 49,722
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 42%
Beta 0.71
Analysts Strong Sell
Price Target $11.00

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 tha...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Address:
350 Collins Street, Suite 4 Level 14, Melbourne, Australia
ButcherBillCutting
ButcherBillCutting Jul. 7 at 4:27 PM
$ATHE Big long fireside chat with detailed Q & A after that I was able to watch Took some notes & need to review I encourage current holders or buyers Considering to check it out when You have an hour of free time Dr. Stamler knows what he’s doing, With his past work & present day https://youtu.be/BMQu6cAc4is?si=sjRDPK5_aKIPmyZQ
0 · Reply
motherlandreturns
motherlandreturns Jul. 3 at 1:16 PM
$ATHE I guess we are still waiting for a buy out or partnership 🤑
1 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 1 at 9:21 PM
$SLS Copied from chat.. I believe $ATHE will be a multibagger (6x) I believe $CING will be a multibagger (8x) I believe SLS will be a multibagger. (20x) I believe $PYPD will be a multi-bagger (10x) I believe RILY will be a multibagger. (4x) I believe ANRO will be a multibagger (15x) Oust will double ( or more) before I sell it. I'm up 40% on Slpd since I mentioned it in the group. And Bar may have found something with poet. My trading account is spread equally across those ... even though I believe in SLS the most. Stick and move.... Stick and move....
2 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jun. 27 at 6:15 PM
$SLS $HYPD Lol, Stocktwits not adjusting for split. Closed this position for a nice profit today though. Gains split between SELLAS, $POET and $ATHE (I'm back to 60k shares finally!!!!)
1 · Reply
GA09
GA09 Jun. 27 at 12:57 PM
$ATHE I have invested and traded several biotech stocks and I have to state that Dr Stamler is the best CEO I have seen so far. He has 3 FDA approvals behind him, passionate about treating Parkinson's related diseases, transparent, honest, pleasant, answers analysts questions in detail and completely transparent, extensive experience and working tirelessly to get the 434 approved and on the market ASAP so people who need this treatment and get it ASAP. This is why I am extremely confident they will find the right partner or will get acquired sooner rather than later (after releasing data in July) and will retain a seat and have a say on 434 and its approval and release and will continue to work on additional indications of 434 to treat Parkinson's related diseases. I would be a buyer on any pullbacks before we get data in July. I also liked the fact that he said he reviews each data scrupulously and is a perfectionist with reviewing data.
0 · Reply
glanvill
glanvill Jun. 26 at 11:58 PM
$ATHE The presentation was excellent. The explanation that the difference between 50mg and 75mg results in the P2 is explained by baseline differences in the treatment group is compelling.
0 · Reply
jetwash
jetwash Jun. 26 at 6:38 AM
$ATHE 45:20 mark - The company last ran profitability models in 2023 with the assumption 434 could improve Orthostatic symptoms. It was 1B peak sales in US alone. NOW, with latest data showing it also improves UMSARS score, it's time to double that .
2 · Reply
theaussiebloke
theaussiebloke Jun. 26 at 1:12 AM
$ATHE Yesterdays presentation is now available on Alteritys presentations site...enjoy
1 · Reply
VicTruth17
VicTruth17 Jun. 26 at 12:18 AM
$ATHE here’s the 3 month chart with that $3.55 gap the MMs will try to fill… they have 2 weeks at most… then it’s off to the races again… We’ll hover around $3.50-$3.70 until July 1st…. Happy tradings and the company is still valued at $2-3b :)
1 · Reply
VicTruth17
VicTruth17 Jun. 25 at 6:53 PM
$ATHE will post my thoughts soon but looking at the 3 month chart and trading patterns… there is a gap to be filled at $3.55… Looking to rebuy within the week… playing with fire but they are burning us any chance they get 😫
2 · Reply
Latest News on ATHE
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 30, 2025, 7:35 AM EDT - 2 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report


Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 5 months ago

Alterity Therapeutics Raises A$40.0 million in Placement


Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 5 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report


Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 8 months ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report


Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report


Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar


Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report


Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Oct 30, 2023, 7:25 AM EDT - 1 year ago

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report


Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Jul 31, 2023, 7:52 AM EDT - 2 years ago

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report


ButcherBillCutting
ButcherBillCutting Jul. 7 at 4:27 PM
$ATHE Big long fireside chat with detailed Q & A after that I was able to watch Took some notes & need to review I encourage current holders or buyers Considering to check it out when You have an hour of free time Dr. Stamler knows what he’s doing, With his past work & present day https://youtu.be/BMQu6cAc4is?si=sjRDPK5_aKIPmyZQ
0 · Reply
motherlandreturns
motherlandreturns Jul. 3 at 1:16 PM
$ATHE I guess we are still waiting for a buy out or partnership 🤑
1 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 1 at 9:21 PM
$SLS Copied from chat.. I believe $ATHE will be a multibagger (6x) I believe $CING will be a multibagger (8x) I believe SLS will be a multibagger. (20x) I believe $PYPD will be a multi-bagger (10x) I believe RILY will be a multibagger. (4x) I believe ANRO will be a multibagger (15x) Oust will double ( or more) before I sell it. I'm up 40% on Slpd since I mentioned it in the group. And Bar may have found something with poet. My trading account is spread equally across those ... even though I believe in SLS the most. Stick and move.... Stick and move....
2 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jun. 27 at 6:15 PM
$SLS $HYPD Lol, Stocktwits not adjusting for split. Closed this position for a nice profit today though. Gains split between SELLAS, $POET and $ATHE (I'm back to 60k shares finally!!!!)
1 · Reply
GA09
GA09 Jun. 27 at 12:57 PM
$ATHE I have invested and traded several biotech stocks and I have to state that Dr Stamler is the best CEO I have seen so far. He has 3 FDA approvals behind him, passionate about treating Parkinson's related diseases, transparent, honest, pleasant, answers analysts questions in detail and completely transparent, extensive experience and working tirelessly to get the 434 approved and on the market ASAP so people who need this treatment and get it ASAP. This is why I am extremely confident they will find the right partner or will get acquired sooner rather than later (after releasing data in July) and will retain a seat and have a say on 434 and its approval and release and will continue to work on additional indications of 434 to treat Parkinson's related diseases. I would be a buyer on any pullbacks before we get data in July. I also liked the fact that he said he reviews each data scrupulously and is a perfectionist with reviewing data.
0 · Reply
glanvill
glanvill Jun. 26 at 11:58 PM
$ATHE The presentation was excellent. The explanation that the difference between 50mg and 75mg results in the P2 is explained by baseline differences in the treatment group is compelling.
0 · Reply
jetwash
jetwash Jun. 26 at 6:38 AM
$ATHE 45:20 mark - The company last ran profitability models in 2023 with the assumption 434 could improve Orthostatic symptoms. It was 1B peak sales in US alone. NOW, with latest data showing it also improves UMSARS score, it's time to double that .
2 · Reply
theaussiebloke
theaussiebloke Jun. 26 at 1:12 AM
$ATHE Yesterdays presentation is now available on Alteritys presentations site...enjoy
1 · Reply
VicTruth17
VicTruth17 Jun. 26 at 12:18 AM
$ATHE here’s the 3 month chart with that $3.55 gap the MMs will try to fill… they have 2 weeks at most… then it’s off to the races again… We’ll hover around $3.50-$3.70 until July 1st…. Happy tradings and the company is still valued at $2-3b :)
1 · Reply
VicTruth17
VicTruth17 Jun. 25 at 6:53 PM
$ATHE will post my thoughts soon but looking at the 3 month chart and trading patterns… there is a gap to be filled at $3.55… Looking to rebuy within the week… playing with fire but they are burning us any chance they get 😫
2 · Reply
Denk333
Denk333 Jun. 25 at 1:56 PM
$ATHE all in all solid call and good news came out of it. I can see a partnership or a buy out sometime in the next 2-3 months… hold and DCA
0 · Reply
theaussiebloke
theaussiebloke Jun. 25 at 1:12 PM
$ATHE In addition to other comments regarding this mornings presentation. Dr Stamler discussed other current treatments, which were antibody treatments through IV administration which had shown they dont penetrate the cell, yet ATH434, has shown and proven that it does, therefore treating the root cause...than also mentioned a pts statement that ATH434 should be in the hands of clinicians ASAP. There was alot to unpack, so I look forward to rewatching it, but absolutely nothing negative apart from a slight time extension.
1 · Reply
GA09
GA09 Jun. 25 at 11:21 AM
$ATHE I liked the call (ATHE). CEO did say they have been approached by multiple pharma companies (from very large to small) and he is (already) having constructive discussions as they have shown a keen interest in 434 and are (probably) waiting for data in July to pull (either) the partnership trigger or a buy-out. He did say they will partner with the right pharma who will give them a seat and a say in whole approval process and ensure the drug is (eventually) approved by the FDA. He also said a partnership would be good for the patients and the investors. He is also scheduling mini-sessions with the FDA and will be presenting data at multiple conferences this year. He also said he would prefer a partnership instead of a secondary resulting in dilution. Overall, the call was very constructive and they do have Orphan Drug Status, Fast Track Designation, a treatment not available for over 20+ years (unmet need), and a team with 3 FDA approvals. They get acquired within 6 months.
1 · Reply
tommy_john
tommy_john Jun. 25 at 12:56 AM
$ATHE $3-3.50 retest and then everyone forgets the call. lol
2 · Reply
tommy_john
tommy_john Jun. 25 at 12:55 AM
$ATHE it’s nice to be holding at a low cost. Meh. These things take time. What really changed except the timeline? Buyers will eat up cheap shares just watch
1 · Reply
Denk333
Denk333 Jun. 25 at 12:17 AM
$ATHE what’s the news this one going south AH and it barely have volume
1 · Reply
VicTruth17
VicTruth17 Jun. 25 at 12:03 AM
$ATHE mixed feelings…. I’ll list the Many catalyst I heard but the AA won’t be applied for until December…
1 · Reply
GA09
GA09 Jun. 24 at 11:44 PM
$ATHE Big Pharma is extremely interested!!!!! Big pharma to small pharma have shown a lot of interest. CEO just mentioned. At least 15 pharma companies are talking to them.
0 · Reply
GA09
GA09 Jun. 24 at 11:04 PM
$ATHE Listening to the call now.
0 · Reply
VicTruth17
VicTruth17 Jun. 24 at 11:02 PM
$ATHE anyone else listening?
1 · Reply
VicTruth17
VicTruth17 Jun. 23 at 5:34 PM
$ATHE What’s the board pumping in their minds? AA application? Partnerships for phase 3? Or self funded p3 in which we will get a nice haircut? No mention of the 202 advance stage? Pumped 💪🏽
1 · Reply
VicTruth17
VicTruth17 Jun. 23 at 1:45 PM
$ATHE the feeling is materializing… let’s see what’s today best price :)
1 · Reply